You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
爾康製藥(300267.SZ):“呋喃妥因”等4種原料藥通過CDE審批
格隆匯 03-01 20:20

格隆匯 3 月 1日丨爾康製藥(300267.SZ)公佈,近日,公司從國家藥品監督管理局藥品審評中心(CDE)“原料藥、藥用輔料和藥包材登記信息公示”平台查詢獲悉,全資子公司湖南湘易康製藥有限公司(“湘易康”)提交的“呋喃妥因”、“煙酰胺”、“鹽酸西替利嗪”、“鹽酸四環素”原料藥(受理號:CYHT1600533、CYHT1600560、CYHT1600557、CYHT1600538)通過了CDE審批。

呋喃妥因,硝基呋喃類抗菌藥,主要用於治療敏感菌所致的泌尿系統感染,如腎盂腎炎、尿路感染、膀胱炎及前列腺炎等;煙酰胺,維生素類藥,主要用於防治糙皮病、口炎、舌炎,也可用於治療心臟傳阻阻滯和提高竇房結功能及抗快速型心律失常;鹽酸西替利嗪,第二代組胺H1受體拮抗劑(抗過敏藥),主要用於治療呼吸系統、皮膚和眼部過敏性疾病,包括常年性變態反應性疾病,如季節性和常年性過敏鼻炎,鼻結膜炎,蕁麻疹,由藥品、食品和昆蟲叮咬引起的過敏反應等;鹽酸四環素,四環素類抗菌藥,主要用於治療衣原體感染、立克次體病、支原體肺炎、迴歸熱等非細菌性感染,也可用於治療布魯菌病、霍亂、兔熱病、鼠咬熱、炭疽、破傷風、鼠疫、放線菌病、氣性壞疽和敏感細菌引起的呼吸系統、膽管、尿路感染及皮膚軟組織感染等。

“呋喃妥因”、“煙酰胺”、“鹽酸西替利嗪”、“鹽酸四環素”原料藥通過CDE審批,有利於公司加快原料藥產業佈局,豐富原料藥品種,完善原料藥產品結構,進一步提升公司核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account